Author

V. Burghi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

J. S. Gutkind· 2 shared A. A. Molinolo· 1 shared A. Goren· 1 shared A. Officer· 1 shared A. Prahallad· 1 shared A. Ruiz-Saenz· 1 shared B. Hann· 1 shared B. Pan· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. S. Gutkind

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

YAP-Driven Oral Epithelial Stem Cell Malignant Reprogramming at Single Cell Resolution

F. Faraji, S. I. Ramirez, L. Clubb, K. Sato, V. Burghi, T. S. Hoang, A. Officer, P. Y. Anguiano Quiroz, W. M. Galloway, Z. Mikulski, K. Medetgul-Ernar, P. Marangoni, K. B. Jones, A. A. Molinolo, K. Kim, , J. S. Gutkind

The paper identifies YAP-driven reprogramming of oral epithelial stem cells into tumor-initiating cells using single-cell multiomics, revealing conserved transcriptional programs linked to poor patient survival.

bioRxiv · Jul 24, 2023Cancer Biology

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

A. Ruiz-Saenz, C. E. Atreya, C. Wang, B. Pan, C. A. Dreyer, D. Brunen, A. Prahallad, D. P. Munoz, D. J. Ramms, V. Burghi, D. S. Spassov, E. Fewings, Y. C. Hwang, C. Cowdrey, C. Moelders, , J.-P. Coppe

This study identifies a SRC-relayed COX2-inflammatory program that drives resistance to BRAF/MEK/EGFR therapies in BRAFV600E colorectal tumors and shows that co-targeting COX2 improves therapeutic outcomes.

bioRxiv · Oct 20, 2022 · PreprintCancer Biology